Inventiva : Résultat des votes de l’Assemblée Générale Mixte du 19 mai 2022

PRESS RELEASE

Results of the votes of the Combined Shareholders' Meeting

of May 19, 2022

Daix (France), Long Island City (New York, United States), May 20, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stagebiopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholicsteatohepatitis (NASH) and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders' Meeting.

The Combined Shareholders' Meeting was held on Thursday May 19, 2022 at 2 p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon (France), under the chairmanship of Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva.

Mr. Frederic Cren proceeded to the usual formalities of the opening of the meeting, in particular to the constitution of the Bureau by appointing Mr. Pierre Broqua and Mr. Jean Volatier, as tellers, as well as Mr. Eric Duranson, as secretary of the Combined Shareholders' Meeting.

All the resolutions submitted to vote have been adopted by the shareholders, with the exception of the 30th resolution which would have empowered the Board of Directors to decide on share capital increases reserved for members of a company savings plan to be set up by the Company.

Pursuant to Article R. 22-10-14 IV. of the French Commercial Code, the Combined Shareholders' Meeting approved, without modification, the compensation policy for corporate officers as presented in the 2021 Universal Registration Document (Part 3.5.1, pages 153 and seq.).

Information on the results of the votes is detailed below:

• Total number of shares composing the share capital: 40 873 551
• Total number of shares with voting rights: 40 802 918

						Ordinary part					Extraordinary part
				Shareholders		Shares		Votes		Shareholders		Shares		Votes
		Shareholders		1		50		50		1		50		50
		present
			0		0		0		0				0
		Proxy to third						0
		parties
			119		122 188		153 298		119		122 188		153 298
		Proxy to the
		Chairman
		Mail votes		87		27 741 130		39 165 996		87		27 741 130		39 165 996
		TOTAL		207		27 863 368		39 319 344		207		27 863 368		39 319 344
		Quorum				68,287%						68,287%
								1

PRESS RELEASE

										Proportion
										of
										represented			Total				For				Against			Abstention
							Number of			share
				State of							number of
	Resolutions					represented			capital
			adoption							votes cast
						shares			(%)
																Number of			in % of votes			Number of			in % of votes			Number of			in % of the
																										total voting
																votes			cast			votes			cast			votes
																										rights
	Resolution 1 - OGM		Adopted	27 863 368		68,169%		39 319 199		39 318 749		> 99,99%		450		< 0,01%		145		-
	Resolution 2 - OGM		Adopted	27 863 368		68,169%		39 319 199		39 318 749		> 99,99%		450		< 0,01%		145		-
	Resolution 3 - OGM		Adopted	27 863 368		68,169%		39 319 199		39 318 749		> 99,99%		450		< 0,01%		145		-
	Resolution 4 - OGM		Adopted	27 863 368		68,169%		39 319 199		39 318 749		> 99,99%		450		< 0,01%		145		-
	Resolution 5 - OGM		Adopted	27 863 368		68,169%		39 319 199		39 318 749		> 99,99%		450		< 0,01%		145		-
	Resolution 6 - OGM		Adopted	27 863 368		68,169%		39 318 514		36 715 609		93,38%		2 602 905		6,62%		830		-
	Resolution 7 - OGM		Adopted	27 863 368		68,169%		39 318 514		36 715 574		93,38%		2 602 940		6,62%		830		-
	Resolution 8 - OGM		Adopted	27 863 368		68,169%		39 318 505		38 457 624		97,81%		860 881		2,19%		839		-
	Resolution 9 - OGM		Adopted	27 863 368		68,169%		38 699 850		38 597 606		99,74%		102 244		0,26%		619 494		-
	Resolution 10 - OGM		Adopted	27 863 368		68,169%		38 699 850		38 597 606		99,74%		102 244		0,26%		619 494		-
	Resolution 11 - OGM		Adopted	27 863 368		68,169%		39 318 514		38 674 432		98,36%		644 082		1,64%		830		-
	Resolution 12 - OGM		Adopted	27 863 368		68,169%		39 318 234		39 317 709		> 99,99%		525		< 0,01%		1 110		-
	Resolution 13 - OGM		Adopted	27 863 368		68,169%		39 317 594		38 598 105		98,17%		719 489		1,83%		1 750		-
	Resolution 14 - OGM		Adopted	27 863 368		68,169%		39 317 594		38 698 105		98,42%		619 489		1,58%		1 750		-
	Resolution 15 - EGM		Adopted	27 863 368		68,169%		39 317 594		37 954 167		96,53%		1 363 427		3,47%		1 750		-

2

PRESS RELEASE

			Proportion
			of
			represented	Total	For		Against		Abstention
		Number of	share
	State of	number of
Resolutions	represented	capital
adoption	votes cast
	shares	(%)
								in % of the
				Number of	in % of votes	Number of	in % of votes	Number of
				total voting
				votes	cast	votes	cast	votes
					rights

Resolution 16 - EGM	Adopted	27 863 368	68,169%	39 317 594	37 954 242	96,53%	1 363 352	3,47%	1 750	-
Resolution 17 - EGM	Adopted	27 863 368	68,169%	39 317 534	39 317 009	> 99,99%	525	< 0,01%	1 810	-
Resolution 18 - EGM	Adopted	27 863 368	68,169%	39 317 594	39 316 769	> 99,99%	825	< 0,01%	1 750	-
Resolution 19 - EGM	Adopted	27 863 368	68,169%	39 319 179	37 080 780	94,31%	2 238 399	5,69%	165	-
Resolution 20 - EGM	Adopted	27 863 368	68,169%	39 319 179	39 102 826	99,45%	216 353	0,55%	165	-
Resolution 21 - EGM	Adopted	27 863 368	68,169%	39 319 179	36 438 322	92,67%	2 880 857	7,33%	165	-
Resolution 22 - EGM	Adopted	27 863 368	68,169%	39 319 179	36 408 145	92,60%	2 911 034	7,40%	165	-
Resolution 23 - EGM	Adopted	27 863 368	68,169%	39 291 157	36 408 141	92,66%	2 883 016	7,34%	28 187	-
Resolution 24 - EGM	Adopted	27 863 368	68,169%	39 319 179	36 436 876	92,67%	2 882 303	7,33%	165	-
Resolution 25 - EGM	Adopted	27 863 368	68,169%	39 291 157	36 407 845	92,66%	2 883 312	7,34%	28 187	-
Resolution 26 - EGM	Adopted	27 863 368	68,169%	39 319 179	36 435 802	92,67%	2 883 377	7,33%	165	-
Resolution 27 - EGM	Adopted	27 863 368	68,169%	39 319 179	36 436 856	92,67%	2 882 323	7,33%	165	-
Resolution 28 - EGM	Adopted	27 863 368	68,169%	39 319 179	36 438 298	92,67%	2 880 881	7,33%	165	-
Resolution 29 - EGM	Adopted	27 863 368	68,169%	39 319 179	36 438 298	92,67%	2 880 881	7,33%	165	-
Resolution 30 - EGM	Rejected	27 863 368	68,169%	39 291 157	15 594 865	39,69%	23 696 292	60,31%	28 187	-
Resolution 31 - EGM	Adopted	27 863 368	68,169%	39 319 179	39 318 434	> 99,99%	745	< 0,01%	165	-
Resolution 32 - EGM	Adopted	27 863 368	68,169%	39 318 989	36 436 917	92,67%	2 882 072	7,33%	355	-

3

PRESS RELEASE

			Proportion
			of
			represented	Total		For		Against		Abstention
		Number of	share
	State of	number of
Resolutions	represented	capital
adoption	votes cast
	shares	(%)
									in % of the
					Number of	in % of votes	Number of	in % of votes	Number of
					total voting
					votes	cast	votes	cast	votes
						rights
Resolution 33 - EGM	Adopted	27 863 368	68,169%	39 291 177	36 409 030	92,66%	2 882 147	7,34%	28 167		-

Resolution 34 - EGM	Adopted	27 863 368	68,169%	39 290 987	36 405 930	92,66%	2 885 057	7,34%	28 357	-
Resolution 35 - EGM	Adopted	27 863 368	68,169%	39 319 199	39 318 749	> 99,99%	450	< 0,01%	145	-
Resolution 36 - OGM	Adopted	27 863 368	68,169%	39 319 199	39 318 749	> 99,99%	450	< 0,01%	145	-

4

PRESS RELEASE

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.

The Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORγ inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

The Company has a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA -

ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.

Important Notice

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to Inventiva's pipeline and preclinical and clinical development plans, future activities, expectations, plans, growth and prospects of Inventiva and the sufficiency of Inventiva's cash resources and cash runway; and whether or to what extent Inventiva may use the share repurchase program and the objectives of any use of the share repurchase program or may undertake any transactions with respect to its securities as authorized by the resolutions approved at the Combined Shareholders' Meeting. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "would", "could", "might", "should", and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Future events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims,

5